Sort
50,496 grants matching “lung cancer”
Development of a lung cancer subtyping diagnostic
$999,554Harold R Garner · Orbit Genomics, Inc. · R44 · FY2024 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
Clinical Development of JS-K for the Treatment of Cancer
$999,423Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2018 · CA
Preventing and treating RSV pneumonia in immunocompromised cancer patients
$999,372Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
Next Generation Smart Nanoparticles
$999,338Paul Alivisatos · Stanford University · U54 · FY2011 · CA
A Point of Care Urine Test to Aid Diagnosis of Aspergillosis
$999,316Kieren A. Marr · Pearl Diagnostics, Inc. · SB1 · FY2025 · AI
PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments
$999,283Archis Bagati · Pyrojas Inc · R44 · FY2025 · CA
Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis
$999,213Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2012 · CA
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
$999,200Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2024 · CA
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
$999,200Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2023 · CA
Clinical Development of JS-K for the Treatment of Cancer
$999,183Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2017 · CA
Growth Factor/Extracellular Matrix Interactions During Branching Morphogenesis
$999,049Matthew P Hoffman · Dental & Craniofacial Research · Z01 · FY2007 · DE
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$998,971Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2025 · CA
OTHER FUNCTIONS "DEVELOPMENT OF A UNI-DIRECTIONAL BRACHYTHERAPY DEVICE FOR THE T
$998,964Kristy Perez · Civatech Oncology, Inc. · N44 · FY2012 · CA
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2020 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2019 · AG
Exisulind for Chemoprevention of Lung Cancer
$998,823H. Lee Moffitt Cancer Ctr &Res Inst · U01 · FY2004 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$998,807Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2017 · CA
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2017 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
2/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)
$998,721Christina Ciecierski · Northeastern Illinois University · U54 · FY2023 · CA
TGF-betas in breast cancer progression
$998,687Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Illinois Oncology Research Association Community Clinical Oncology Program
$998,654John W Kugler · Oncology-Hematology Assoc-Central Ill · U10 · FY2009 · CA
Enhancing Primary Care Capacity for Cancer Survivorship Care Delivery in Community Health Clinics
$998,444Bijal A. Balasubramanian · University Of Texas Hlth Sci Ctr Houston · U01 · FY2024 · CA
CCCWFU Research Base Grant
$998,208Wake Forest University Health Sciences · U10 · FY2003 · CA